Treatment | Page 384 of 465

Dengue Fever :: Homeopathy in dengue fever

Homoeopathic system of medicine can treat and prevent dengue fever (DF) and dengue hemorrhagic fever (DHF) by immuno-modulation of the patients without any side and adverse effects. Homeopathy has been used successfully in the others countries apart from India in the past. The selection of homoeopathic drugs in these cases depends upon the individual response to infection and virulence of the virus. The symptomatology of the patients those who are having dengue fever and dengue hemorrhagic are studied to decide about the curative and preventive homoeopathic medicines for any patient as well as epidemic as a whole.

Breast Cancer :: Critical gaps in breast cancer patient education and communication

Results from a recent survey of European women with early breast cancer, presented for the first time at the European Society for Medical Oncology (ESMO) congress, show that the information needs of patients are not being met and that there is an unacceptably low level of patient involvement in potentially life-extending treatment decisions. The survey revealed that older women, those with a low level of education and those without Internet access are particularly uninformed.

Breast Cancer :: Genetic alterations may explain racial disparity in breast cancer

Molecular and genetic alterations that cause tumors and drive the course of disease may someday explain the differences in incidence and mortality between African American and European American breast cancer patients. This is the conclusion of a literature review by a research team at Roswell Park Cancer Institute (RPCI) led by Christine B. Ambrosone, PhD, Chair of Epidemiology at RPCI. Results of the study are published in the September edition of Cancer Research.

Multiple Sclerosis :: Treatment of relapsing-remitting multiple sclerosis

UCB (Euronext Brussels: UCB) and Biogen Idec (NASDAQ: BIIB) today announced a global collaboration to jointly develop and commercialize CDP323 for the treatment of relapsing-remitting multiple sclerosis (MS) and other potential indications. CDP323 is an orally active small molecule alpha4-integrin inhibitor expected to enter Phase II clinical trials next year.

Psychiatry :: Blackwell publishing launches ‘early intervention in psychiatry’

Blackwell Publishing is set to break into an exciting new area of clinical psychiatry with its new journal – Early Intervention in Psychiatry. The journal will be launched at the IEPA Conference in Birmingham in October 2006, and will publish its inaugural issue in February 2007.

Sleep :: Australasian sleep association, Perth – conference highlights

Snorers Cause Bed Partners to have EEG Arousals (91)Sean Tolhurst, University of Queensland and SNORE Australia – A new study has found that people with sleep apnea cause their bed-partners to have EEG arousals and sleep disturbance. Up until now there has been limited scientific information into how much a patient with Obstructive Sleep Apnea disturbs a sleeping bed partner. This study investigated the impact that snoring and sleep apnea events have on the bed-partner.

Health :: Prevention and treatment are leading contributors to mental health crisis

One in four U.S. adults suffer from a diagnosable mental disorder, yet they face barriers to equal access to treatment and preventive health services, public health experts said today at a forum releasing new research examining the impact of mental illness on the nation’s health from the October 2006 issue of the American Journal of Public Health.

Lung cancer :: New cancer drug AS1404 Antisoma extends life for lung cancer patients

Lung cancer patients treated with an experimental new drug lived over a third longer than patients treated with standard chemotherapy, according to data released. The phase II study, carried out by UK biotech company Antisoma plc, looked at 70 patients with non-small cell lung cancer (NSCLC), the most common type of lung cancer.

Multiple Sclerosis :: Fty720 – fingolimod reduces multiple sclerosis symptoms

The developmental oral therapy FTY720 (fingolimod) has demonstrated sustained benefits over two years in patients suffering from relapsing multiple sclerosis (MS), indicating that it could provide an important new option for treating this disabling neurological disease estimated to affect more than 2.5 million people worldwide.

Health :: Antibiotic Ceftobiprole shows promise against MRSA infections

Johnson & Johnson Pharmaceutical Research and Development, L.L.C. today announced that ceftobiprole, a novel cephalosporin(1) antibiotic in Phase III clinical trials, was found to be active against complicated skin infections caused by common, potentially deadly bacteria, including MRSA. These data were from two poster presentations given at the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). These data also were highlighted by ICAAC. Ceftobiprole is being co-developed with Basilea Pharmaceutica, Ltd. through an exclusive worldwide collaboration.